Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Myriad Genetics Inc (NQ: MYGN )

23.72 +0.09 (+0.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics Inc

< Previous 1 2 3 Next >
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry 
From Myriad Genetics, Inc.
Via Globe NewsWire
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Earnings Preview For Myriad Genetics
 
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Participate in Upcoming Healthcare Conferences
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
From Myriad Genetics, Inc.
Via Globe NewsWire
3 Small Caps That Have Big Upside
If market sentiment stays bullish, small caps with depressed shares prices and valuation could turn into big-time outperformers. 
Via MarketBeat
Topics Economy
Exposures Economy
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Insiders Selling DocuSign, Adobe And 2 Other Stocks
The Nasdaq settled higher by 2% on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
 
Via Benzinga
Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Myriad Genetics, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 75 companies set new 52-week lows. 
Via Benzinga
Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model
Myriad’s MyRisk™ Hereditary Cancer test with RiskScore® provides a personalized breast cancer risk assessment for women of all ancestries 
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment
From Myriad Genetics, Inc.
Via Globe NewsWire
GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care
Survey finds primary care providers wish patients would raise mental health concerns so they can provide better overall care 
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting
From Myriad Genetics, Inc.
Via Globe NewsWire
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information
From Myriad Genetics, Inc.
Via Globe NewsWire
Why Shares of Myriad Genetics Dropped 24% This Week
The genetic-testing company announced an acquisition and lowered its guidance. 
Via The Motley Fool
New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
From Myriad Genetics, Inc.
Via Globe NewsWire
Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping around 70 points on Tuesday. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Why Abiomed Shares Are Trading Higher By Over 50%? Here Are 60 Stocks Moving In Tuesday's Mid-Day Session
Gainers Safe-T Group Ltd (NASDAQ: SFET) shares surged 63.7% to $0.4910 as the company said its privacy application reached over 5,000,000 downloads. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.